Last reviewed · How we verify

Clopradone — Competitive Intelligence Brief

Clopradone (ETOPERIDONE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective Serotonin Reuptake Inhibitors. Area: Neuroscience.

phase 2 Selective Serotonin Reuptake Inhibitors 5-hydroxytryptamine receptor 1A, D(2) dopamine receptor, Histamine H1 receptor Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Clopradone (ETOPERIDONE). Clopradone works by blocking the reabsorption of serotonin in the brain, allowing more of this neurotransmitter to be available for communication between nerve cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Clopradone TARGET ETOPERIDONE phase 2 Selective Serotonin Reuptake Inhibitors 5-hydroxytryptamine receptor 1A, D(2) dopamine receptor, Histamine H1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective Serotonin Reuptake Inhibitors class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clopradone — Competitive Intelligence Brief. https://druglandscape.com/ci/etoperidone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing